Foley Secures Rare Inter Partes Review Wins for Patent Owner Supernus Pharmaceuticals

10 December 2014 Media Contact: Jill Chanen News

Foley secured three significant inter partes review victories on behalf of Supernus Pharmaceuticals, Inc. and Galderma S.A. for a pharmaceutical product, which represents one of the first inter partes reviews to reach a final decision in favor of the patent owner, where the patents were the subject of a parallel Hatch-Waxman patent litigation. The inter partes reviews were filed by a “generic” company that filed an Abbreviated New Drug application to market a generic version of the product Oracea®.

The Foley team, led by Stephen Maebius, included Andrew Baluch, George Quillin, and Sunit Talapatra.

Related Services

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ